Abstract
Background Atrial fibrillation (AF) is the most common sustained arrhythmia worldwide. However, there is no data on AF inpatient management strategies and clinical outcomes in Syria.
Objectives This study aims to navigate AF inpatient management and cardiovascular (CV) mortality in a tertiary cardiology centre in Latakia, Syria.
Methods A single-centre retrospective observational cohort study was conducted at Tishreen’s University Hospital, Latakia, Syria, from June 2021 to June 2023. We included patients ≥16 years of age presenting and being treated for AF as the primary diagnosis at the emergency department. Medical records were examined for patient demographics, laboratory results, treatment plans and inpatient details. Inpatient cardiovascular mortality was the primary outcome of interest.
Results The study included 596 patients. The median age was 58 and 61% were males. Only 121 patients (20.3%) were known to have AF. Rhythm control strategy was persuaded in 39% of patients, with Amiodarone being the only agent utilised while the rest adopted a rate control approach. CV Mortality occurred in 28 patients (4.7%). The presence of smoking (aOR: 1.6, 95% CI: 1.3 to 2.1, P=0.04), thyroid disease (aOR= 9.7, 95% CI= 1.2 to 91.6, P<0.001), COPD (aOR: 82, 95% CI: 12.7 to 711, P<0.001) and valvular heart disease (VHD) (aOR= 9.1, 95% CI: 1.7 to 55.1, P<0.001) were independent risk factors of cardiovascular inpatient mortality.
Conclusion Current smoking, thyroid disease, COPD and VHD were independent risk factors of inpatient cardiovascular mortality with AF in Syria. Elective rhythm control was challenging due to limited resources.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
No funding was provided to this study.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethical approval was obtained by the hospital board and the ethical board at Tishreen's University Hospital (reference: 277/A).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
Available upon request of the corresponding author
